Company: IMNN
Filing Date: 2025-05-19
Form Type: S-1/A
Source: 0001641172-25-011388
Chunk: 29

Company: Imunon, Inc.
Filing Date: 2025-05-19
Form: S-1/A
Chunk 29
---
 of this prospectus, and we may not sell all or any of the
securities we are offering. As a result, we may receive significantly less in net proceeds. Based on the assumed offering price set forth
above, we estimate that our net proceeds from the sale of 75%, 50%, and 25% of the securities offered in this offering would be approximately
$5.3 million, $3.4 million, and $1.6 million, respectively, after deducting the estimated Placement Agent fees and estimated
offering expenses payable by us, and assuming no issuance of any pre-funded warrants and assuming no exercise of the common warrants.
These estimates exclude the proceeds, if any, from the exercise of common warrants offered hereby. We will only receive additional proceeds
from the exercise of the common warrants we are selling in this offering if Stockholder Approval is obtained and such common warrants
are exercised for cash. However, the common warrants may be exercised by way of a “zero exercise price” exercise,
meaning that the holder thereof may not pay a cash purchase price upon exercise, but instead would receive upon such exercise three shares
of our Common Stock for every common warrant they exercise. Accordingly, if Stockholder Approval is obtained and the common warrants
are exercisable, we will likely not receive any additional funds upon the exercise of common warrants.

Each $0.10 increase
(decrease) in the assumed public offering price of $0.48 per share of Common Stock and accompanying common warrant would increase
(decrease) our net proceeds from this offering by approximately $1.6 million ($1.6 million), assuming that the number of
shares of Common Stock offered by us remains the same, and after deducting estimated Placement Agent fees and estimated offering expenses
payable by us. An increase (decrease) of 1,000,000 in the number of shares of Common Stock and accompanying common warrants offered by
us would increase (decrease) our net proceeds from this offering by approximately $0.4 million ($0.4 million), assuming
no change in the public offering price per share of Common Stock and accompanying common warrant, and after deducting estimated Placement
Agent fees and estimated offering expenses payable by us.

We intend to use the net proceeds of this offering for general corporate purposes, including the clinical development of our lead product candidate (IMNN-001), capital expenditures and working capital.

Our expected use of net proceeds from the offering represents our current intentions based upon our present plans and business condition